Moomoo AI 已提取核心信息
NexImmune, Inc. has announced the offering of 117,000 shares of its common stock at a purchase price of $12.05 per share to an institutional investor, as detailed in a securities purchase agreement dated February 2, 2024. Additionally, the company is offering pre-funded warrants to purchase up to 187,731 shares of common stock to the same purchaser, in lieu of common stock that would result in the purchaser owning more than 9.99% of NexImmune's outstanding common stock post-transaction. Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.001 per share and is immediately exercisable. The offering also includes a concurrent private placement of common stock warrants to purchase up to 304,731 shares of common stock, which are...Show More
NexImmune, Inc. has announced the offering of 117,000 shares of its common stock at a purchase price of $12.05 per share to an institutional investor, as detailed in a securities purchase agreement dated February 2, 2024. Additionally, the company is offering pre-funded warrants to purchase up to 187,731 shares of common stock to the same purchaser, in lieu of common stock that would result in the purchaser owning more than 9.99% of NexImmune's outstanding common stock post-transaction. Each pre-funded warrant is exercisable for one share of common stock at a nominal exercise price of $0.001 per share and is immediately exercisable. The offering also includes a concurrent private placement of common stock warrants to purchase up to 304,731 shares of common stock, which are not registered under the Securities Act and are being offered under an exemption. The common stock is listed on The Nasdaq Capital Market under the symbol 'NEXI.' The last reported sale price of NexImmune's common stock was $15.19 per share as of February 1, 2024. The securities offered are expected to be delivered on or about February 6, 2024, subject to customary closing conditions.
NexImmune, Inc.宣布以每股12.05美元的收购价向机构投资者发行11.7万股普通股，详情见2024年2月2日的证券购买协议。此外，该公司还提供预先注资的认股权证，向同一买家购买多达187,731股普通股，以代替普通股，这将使买方在交易后拥有NexImmune已发行普通股的9.99％以上。每份预先注资的认股权证均可按每股0.001美元的名义行使价行使一股普通股，并可立即行使。此次发行还包括同时私募普通股认股权证，以购买多达304,731股普通股，这些普通股未根据《证券法》注册，是根据豁免发行的。普通股在纳斯达克资本市场上市，股票代码为 “NEXI”。截至2024年2月1日，NexImmune普通股上次公布的销售价格为每股15.19美元。所发行的证券预计将于2024年2月6日左右交割，但须遵守惯例成交条件。
NexImmune, Inc.宣布以每股12.05美元的收购价向机构投资者发行11.7万股普通股，详情见2024年2月2日的证券购买协议。此外，该公司还提供预先注资的认股权证，向同一买家购买多达187,731股普通股，以代替普通股，这将使买方在交易后拥有NexImmune已发行普通股的9.99％以上。每份预先注资的认股权证均可按每股0.001美元的名义行使价行使一股普通股，并可立即行使。此次发行还包括同时私募普通股认股权证，以购买多达304,731股普通股，这些普通股未根据《证券法》注册，是根据豁免发行的。普通股在纳斯达克资本市场上市，股票代码为 “NEXI”。截至2024年2月1日，NexImmune普通股上次公布的销售价格为每股15.19美元。所发行的证券预计将于2024年2月6日左右交割，但须遵守惯例成交条件。
有用
没用